Abstracts tagged "Cohort Study"

Abstract Number: 0561 • ACR Convergence 2023
Frequency of Anti-Ro Antibodies in Systemic Lupus Erythematosus Patients: Insights from Multicenter and National Registry
Lucia Margarita Mendoza Martinez¹, Joan Manuel Dapeña¹, Juan Manuel Bande¹, Maria Alejandra Medina¹, Silvia Papasidero¹, José caracciolo¹, Rosana Quintana², Lucila Garcia², Carla Andrea Gobbi², Sandy Sapag Durán², Alberto Spindler², Analia Patricia Alvarez², Cecilia Pisoni², Catalina Gomez², Raúl Hector Paniego², María Julia Santa cruz², Luciana Gonzalez Lucero², Rodrigo Aguila Maldonado², Sergio Gordon², Julia Romero², Gretel Rausch², Alberto Allievi², Alberto Omar Orden², johana zacariaz hereter³, Roberto Baéz², Andrea Vanesa González², Juan Manuel Vandale², Mario Alberto Goñi², Victor Caputo⁴, María Silvia Larroudé², Graciela Gómez², Josefina Marin², Victoria Collado², Gazzoni María Victoria², Marcos David Zelaya², Mónica Sacnún², Romina Rojas Tessel², Maira Alejandra Arias Saavedra², Maximiliano Machado Escobar², Pablo Astesana², Ursula Vanesa Paris², Bernando A. Pons-Estel² and Mercedes García⁵, ¹Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ²Study Group of the Argentine Society of Rheumatology for Systemic Lupus Erythematosus, Buenos Aires, Argentina, ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Militar Central, Buenos Aires, Argentina, ⁵Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina
Background/Purpose: Anti-Ro antibodies can be detected in 40% of patients with systemic lupus erythematosus (SLE) and have been associated with various clinical manifestations of the…
Abstract Number: 1075 • ACR Convergence 2023
Impact of Immunosuppression on the Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Rheumatic Autoimmune Disease: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Lourdes Gonzalez Arreola¹, Carrie Ye², Marie Hudson³, Janet Roberts⁴, Janet Pope⁵, Thomas Appleton⁵, Sabrina Hoa⁶, Aurore Fifi-Mah⁷, Nancy Maltez⁸, Alexandra Saltman⁹, Megan Himmel⁹, Ines Colmegna¹⁰, Alexandra Ladouceur¹¹, Anthony Obrzut¹, Jeremiah Tan¹², David Moon², Tatiana Nevskaya⁵, Emma Schmidt¹³, Lindsay Cho⁴, Nader Toban¹⁴ and Shahin Jamal¹⁵, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²University of Alberta, Edmonton, AB, Canada, ³McGill University, Montréal, QC, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵University of Western Ontario, London, ON, Canada, ⁶University of Montreal, Brossard, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸The Ottawa Hospital, Ottawa, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, ¹⁰The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ¹²Arthritis Research Canada, Vancouver, Canada, Vancouver, BC, Canada, ¹³University of British Columbia, Vancouver, BC, Canada, ¹⁴Centre Hospitalier de l'Université de Montréal, Dollard-des-Ormeaux, QC, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have changed the landscape of treatment for many cancers. However, most cancer clinical trials for ICI excluded patients with pre-existing…
Abstract Number: 1632 • ACR Convergence 2023
Incident Malignancies in Patients with Rheumatoid Arthritis in Daily Rheumatological Care
Martin Schaefer¹, Yvette Meissner¹, Bernhard Manger², Sylvia Berger³, Karin Rockwitz⁴, Anne Regierer⁵ and Anja Strangfeld¹, ¹German Rheumatism Research Center, Berlin, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Rheumatologist, Naunhof, Germany, ⁴Rheumatologist, Goslar, Germany, ⁵Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Background/Purpose: In 2021, the European and US-American regulatory agencies EMA and FDA issued warnings about malignancy risk associated with the Janus kinase inhibitor (JAKi) tofacitinib…
Abstract Number: 2308 • ACR Convergence 2023
The Association Between Poverty and SLE Disease Burden: Experiences from a Saint Lucian Cohort
Amanda King¹, Catherine Brown², Cleopatra Altenor¹, Timothy Niewold³ and Ashira Blazer³, ¹Bay Medical Centre, Castries, Saint Lucia, ²The University of the West Indies, Bridgetown, Barbados, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Poverty increases non-communicable disease risk, however its influence on systemic lupus erythematosus (SLE) burden is poorly understood. Non-White racial/ethnic groups, particularly of African origin,…
Abstract Number: 005 • 2023 Pediatric Rheumatology Symposium
Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study
Emily Zhang¹, Gabrielle Alonzi¹, Madeline Hlobik¹, Esra Meidan¹, Mindy Lo¹, Olha Halyabar², Melissa Hazen¹, Ezra Cohen³, Lauren Henderson¹, Siobhan Case⁴, Margaret Chang¹, Camille Frank¹, Ankana Daga¹, Jonathan Hausmann⁵, Ahmad Bakhsh¹, Liyoung Kim¹, Daniel Ibanez¹, Holly Wobma¹, Mia Chandler⁶, Fatma Dedeoglu¹, Robert Sundel¹, Peter Nigrovic¹, Karen Costenbader⁷, Mary Beth Son¹ and Joyce Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Children's Hospital/Boston Medical Center, Boston, MA, ³Boston Medical Center, Boston, MA, ⁴Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁵Boston Children's Hospital / Massachusetts General Hospital, Boston, MA, ⁶Boston Children's Hospital; Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: The morbidity of chronic glucocorticoid (GC) use is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The newly developed pediatric glucocorticoid…
Abstract Number: 0467 • ACR Convergence 2022
All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study
Jacob Sode¹, Jens Rathmann¹, Anna Wilding², Carl Turesson³ and Aladdin Mohammad¹, ¹Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Most previous studies have demonstrated a similar overall survival in patients with GCA compared to the background population. However, we have previously reported an…
Abstract Number: 1068 • ACR Convergence 2022
Anti-vinculin Antibodies in Systemic Sclerosis: Associations with Slow Gastric Transit and Extra-Intestinal Clinical Phenotype
Maria Herran¹, Brit Adler², Jamie Perin³, Walter Morales⁴, Mark Pimentel⁵ and Zsuzsanna McMahan⁶, ¹School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia, ²Johns Hopkins University, Division of Rheumatology, Baltimore, MD, ³John Hopkins University, Baltimore, MD, ⁴Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, ⁵Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai, Los Angeles, CA, ⁶Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: The gastrointestinal tract is commonly affected in systemic sclerosis (SSc). Prior studies have reported an association between higher levels of anti-vinculin antibodies and gastrointestinal…
Abstract Number: 1443 • ACR Convergence 2022
Lymphadenopathy in Systemic Lupus Erythematosus: Clinical Characteristics and Prognostic Features
Eleni Papachristodoulou, Daniel Magliulo and Vasileios Kyttaris, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Patients with SLE often develop lymphadenopathy (LAD), regarded as a relatively common manifestation of the disease. Its clinical significance has not yet been elucidated.…
Abstract Number: 1853 • ACR Convergence 2022
A Comparitive Study of NLRP3- and NLRP12-autoinflammatory Disease
Mark Yun, Brianne Navetta-Modrov, Hafsa Nomani, Jie Yang and QingPing Yao, Stony Brook University, Stony Brook, NY
Background/Purpose: NLRP3-associated autoinflammatoy disease (NLRP3-AID) and NLRP12-AID are rare autosomal dominant diseases. FACS1(familial cold autoinflammatory syndrome type 1), a subset of NLRP3-AID, is thought to…
Abstract Number: 2076 • ACR Convergence 2022
Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus
Zahi Touma¹, Sheena Kayaniyil², Anna Parackal², Dennisse Bonilla¹, Jiandong Su¹, Christina Qian³, Sally Miller³, Shelagh Szabo³ and Shelly Chandran², ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²AstraZeneca, Mississauga, ON, Canada, ³Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada
Background/Purpose: The effectiveness of current standard of care treatment including corticosteroids (CS) in Systemic Lupus Erythematosus (SLE) is limited and has potential side-effects. Given the…
Abstract Number: 0469 • ACR Convergence 2022
Factors Associated with Corticosteroid Dosing in the Management of Giant Cell Arteritis
Loukas Kakoullis and Shiv Sehra, Mount Auburn Hospital, Cambridge, MA
Background/Purpose: Corticosteroids are the cornerstone of therapy in patients with giant cell arteritis (GCA). Tapering regiments vary considerably in both dose and duration, while relapses…
Abstract Number: 1070 • ACR Convergence 2022
Discordance of Patient, Physician and Nurse Practitioner Assessment of Disease Burden in Systemic Sclerosis
Maylen Nordgård Carstens¹, Håvard Fretheim¹, Imon Barua¹, Henriette Didriksen², Torhild Garen¹, Øyvind Midtvedt¹, Øyvind Molberg³ and Anna-Maria Hoffmann-Vold¹, ¹Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Moss, Norway, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Assessment of disease burden is crucial in the management of systemic sclerosis (SSc). The patient global assessment (PatGA) is a patient self-reported measure widely…
Abstract Number: 1449 • ACR Convergence 2022
Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study
Lifan Zhang¹, xiaoqing zou², Lantian Xie³, Jianghao Liu³, zhengrong yang⁴, qifei cao⁴, Chunlei Li⁵, Xiaochuan Sun⁵, Fengchun ZHANG⁶, Yan Zhao⁷, Xiaofeng Zeng⁸ and Xiaoqing Liu¹, ¹Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China, ⁴Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁶Peking Union Medical College Hospital, Beijing, China, ⁷Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: The burden of tuberculosis (TB) and systemic lupus erythematosus (SLE) in China are both the second largest in the world. Patients with SLE are…
Abstract Number: 1858 • ACR Convergence 2022
A Multi-center Clinical Cohort Study of Chinese Anti-synthetase Syndrome Patients
mingwei tang¹, Qian Wang¹, wei Wei², Pingting Yang³, Xinwang Duan⁴, Hongbin Li⁵, Chanyuan Wu⁶, JIULIANG ZHAO⁷, jia shi¹, Xiaomei Leng⁸, Xinping Tian¹, MENGTAO LI⁹, Yan Zhao¹ and Xiaofeng Zeng¹⁰, ¹Peking Union Medical College Hospital, Beijing, China, ²Tianjin Medical University General Hospital, Tianjin, China, ³The First Hospital of China Medical University, Shenyang, China, ⁴the Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁵Inner Mongolia Medical University, Hohhot City, China, ⁶Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, ⁷Beijing Union Medical College Hospital, Beijing, China, ⁸Peking Union Medical College Hospital, Department of Rheumatology and Clinical Immunology, Beijing, China, ⁹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, ¹⁰Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: Based on the Chinese Rheumatology Data Center Inflammatory Myopathy Registry (CRDC-MYO), this study aimed to describe the baseline characteristics of a subgroup of patients…
Abstract Number: 2088 • ACR Convergence 2022
Achieving Systemic Lupus Erythematosus Disease Control or Low Lupus Disease Activity State Is Associated with Lower Rates of Organ Damage: Results from the Hopkins Lupus Cohort
Jacob N. Hunnicutt¹, Mary E. Georgiou², Anna Richards², Holly Quasny³, Laurence S Magder⁴, Daniel W. Goldman⁵ and Michelle Petri⁵, ¹GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA, ²GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, ³GlaxoSmithKline, Clinical Sciences, Research Triangle Park, NC, ⁴University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: The treatment target for systemic lupus erythematosus (SLE) is remission or, if this cannot be reached, the lowest disease activity achievable with the least…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].